Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Overtakes Fresenius In US Injectables

Injectables Growth Across Regions In 2021 Accompanies Expansion Through Acquisitions

Executive Summary

Hikma says it is now ranked second only to Pfizer in terms of US generic injectables volumes – overtaking rival Fresenius – as it continues to expand in the segment, including via recent acquisitions. Meanwhile, the firm is also laying the groundwork for a US biosimilars business.

You may also be interested in...



Hikma Differentiates With Succinylcholine Chloride PFS

Hikma has debuted a pre-filled syringe formulation of succinylcholine chloride in the US, representing the first FDA-approved PFS version of the product to be launched in the market.

Hikma Eyes Return To Growth After Further Cutting Generics Forecasts

Hikma has once again downgraded its expectations for its generics business in 2022 as it revealed a first-half drop of 18% in sales for the unit. However, injectables and branded increases helped to offset the decline, while the company maintained that generics growth was on the horizon in 2023.

Hikma Strikes Deal For Celltrion’s Yuflyma

Hikma has added yet another Celltrion biosimilar to its marketing partnership in the Middle East and North Africa region, in the form of the Korean company’s Yuflyma higher-strength adalimumab rival to Humira.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel